Evonik gets go-ahead, for now
German ECM bankers were last week reluctant to write off the chances of speciality chemicals firm Evonik in the IPO market even as other deals fell away.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts